Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors for overall survival in patients with advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: A post-hoc analysis of JCOG1213.
Authors
Hidekazu Hirano
National Cancer Center Hospital, Tokyo, Japan
Hidekazu Hirano , Kenro Hirata , Yoshitaka Honma , Chigusa Morizane , Nozomu Machida , Ken Kato , Takuji Okusaka , Narikazu Boku , Shigeki Sekine , Nobuyoshi Hiraoka , Gakuto Ogawa , Yusuke Sano , Yuichi Shibuya , Masanobu Takahashi , Nao Fujimori , Motoo Nomura , Yuichiro Doki , Makoto Ueno , Takaki Yoshikawa , Hiroya Takeuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000014795
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 594)
DOI
10.1200/JCO.2024.42.3_suppl.594
Abstract #
594
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).
First Author: Chigusa Morizane
Poster
2018 Gastrointestinal Cancers Symposium
Is there a role for histology based treatment choice in advanced gastric cancer (GC)?
First Author: Rosalba Barile
Poster
2012 ASCO Annual Meeting
Multicenter retrospective analysis of systemic chemotherapy for advanced poorly differentiated neuroendocrine carcinoma of the digestive system.
First Author: Nozomu Machida